Redeye is positive for ISAB’s continued high sales activity. Today, the company announced it has signed a new IRS order worth SEK1.2m with a large generic pharma company. We look forward to the Q3’22 report at the end of November and reiterate our Base Case of SEK23.

Link to the analysis